Development of Antibodies and ADCs

At 3D-PharmXchange, we have extensive experience in the development of antibodies and antibody-drug conjugates (ADCs), supporting companies from late-stage research to clinical trials and regulatory approval. Currently, we are engaged in 65 ongoing projects, with 14 specifically focused on the development of antibodies or ADCs, reflecting our deep expertise in advancing these complex biologics.

Our strength lies in seamlessly integrating all four key disciplines of drug development: CMC, non-clinical development, clinical development, and regulatory affairs, to ensure a streamlined and cost-effective pathway to market.

Our team supports the development of the manufacturing processes to ensure the scalability and quality of antibodies and ADCs, addressing the complexities of conjugation, formulation, and analytical development. In non-clinical development, we design tailored preclinical programs to demonstrate therapeutic efficacy and safety, supporting smooth transition into the clinic. Our clinical development expertise ensures well-designed trials that align with regulatory expectations and patient needs, while our regulatory affairs specialists provide strategic guidance to navigate complex approval pathways efficiently. 

By integrating these disciplines, we help companies accelerate development, mitigate risks, and bring innovative antibody-based therapies to patients faster and more (cost) effectively.